Risk Identification of the GlucoTab System in Routine Use
NCT ID: NCT02053077
Last Updated: 2023-05-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
150 participants
OBSERVATIONAL
2014-02-28
2016-06-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy, Usability Study of the GlucoTab System for Glycaemic Management in Type 2 Diabetic Patients at General Wards
NCT01932775
Performance of a Tablet Based Workflow and Decision Support System With Incorporated Software Algorithm Used for Glycaemic Management
NCT01766752
DigiDiab Pilot Spain - Nursing Home and Domiciliary Nursing Care
NCT06605859
DigiDiab Evaluation Domiciliary Nursing Care
NCT06616779
Performance and Safety Evaluation of a Novel Non-invasive Glucose Monitoring Device and Evaluation of the Instructions for Use
NCT04033042
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* type 2 diabetes or new-onset hyperglycaemia which require s.c. insulin therapy during hospital stay
* diabetes therapy supported by GlucoTab system
Exclusion Criteria
* intravenous insulin therapy
* hyperglycaemic episodes (ketoacidosis, hyperosmolar state) if they require intravenous insulin therapy
* gestational diabetes or pregnancy
* known or suspected allergy to certain insulin types, named in the user manual
* total parenteral nutrition (TPN)
* any mental condition rendering the patient incapable of giving his consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Graz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pieber Thomas, MD
Univ. Prof. Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas R. Pieber, Univ.Prof.Dr
Role: PRINCIPAL_INVESTIGATOR
Medical University of Graz
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University of Graz
Graz, Styria, Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ClinDiab-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.